Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | IL2 | P60568 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029389 | 0.90 | MEN1 (0.55) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL13640660 | 0.89 | MEN1 (0.61) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL16017437 | 0.85 | MEN1 (0.65) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL5029476 | 0.84 | IL2 (0.49) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL8227593 | 0.81 | MEN1 (0.54) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL14887708 | 0.81 | MEN1 (0.60) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL16017438 | 0.80 | MEN1 (0.58) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL5033824 | 0.78 | IL2 (0.47) | MEN1KMT2AIL2MAPTJAK2 | |
| SCHEMBL7922970 | 0.77 | MEN1 (0.57) | MEN1KMT2AMAPTJAK2JAK1 | |
| SCHEMBL2315832 | 0.77 | KMT2A (0.57) | MEN1KMT2AMAPTJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1983831-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8314130-B2 | Compounds inclunding substituted pyridines for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314130-B2 | Compounds inclunding substituted pyridines for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1983831-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | MEN1 4111/4885KMT2A 4100/4885IL2 11/4885 |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | MEN1 4111/4885KMT2A 4100/4885IL2 11/4885 |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | MEN1 4111/4885KMT2A 4100/4885IL2 11/4885 |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | MEN1 4085/4885KMT2A 3327/4885IL2 55/4885 |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, NOD1 | MEN1 4140/4885KMT2A 3976/4885IL2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.